Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · Real-Time Price · USD
459.41
-0.21 (-0.05%)
At close: Jul 7, 2025, 4:00 PM
458.00
-1.41 (-0.31%)
After-hours: Jul 7, 2025, 6:22 PM EDT
-0.05%
Market Cap 117.98B
Revenue (ttm) 11.10B
Net Income (ttm) -988.90M
Shares Out 256.80M
EPS (ttm) -3.84
PE Ratio n/a
Forward PE 24.30
Dividend n/a
Ex-Dividend Date n/a
Volume 1,589,362
Open 460.00
Previous Close 459.62
Day's Range 455.79 - 461.25
52-Week Range 377.85 - 519.88
Beta 0.41
Analysts Buy
Price Target 508.91 (+10.78%)
Earnings Date Jul 31, 2025

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 1991
Country United States
Stock Exchange NASDAQ
Ticker Symbol VRTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 25 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price target is $508.91, which is an increase of 10.78% from the latest price.

Price Target
$508.91
(10.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vertex's next-generation cystic fibrosis drug gets EU approval

Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.

6 days ago - Reuters

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment ...

6 days ago - Business Wire

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agre...

14 days ago - Business Wire

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET Company Participants James Markmann - Corporate Part...

15 days ago - Seeking Alpha

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORW...

17 days ago - Business Wire

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief S...

27 days ago - Seeking Alpha

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with ...

4 weeks ago - Business Wire

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ET Company Participants Reshma Kewalramani - President & CEO Conference Cal...

5 weeks ago - Seeking Alpha

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Ver...

6 weeks ago - Seeking Alpha

Vertex to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...

7 weeks ago - Business Wire

Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft

The Investment Committee give you their top names to watch for the second half.

Other symbols: MSFTPLTRWYNN
2 months ago - CNBC Television

Vertex On Track To Significantly Improve Revenue And Earnings By 2030

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain manage...

2 months ago - Seeking Alpha

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

On Monday, Vertex Pharmaceuticals Incorporated VRTX reported lower-than-expected first-quarter 2025 earnings.

2 months ago - Benzinga

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.

The company discloses narrower-than-expected access to its new painkiller.

2 months ago - Barrons

Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More

U.S. equities were lower at midday as the market watched for any possible deals involving Trump administration tariffs and awaited tomorrow's statement from the Federal Reserve policymakers following ...

Other symbols: CEGDASH
2 months ago - Investopedia

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday.

Other symbols: FNICHR
2 months ago - Benzinga

Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)

Vertex Pharmaceuticals missed Q1 revenue and EPS estimates but this is not a cause for concern as the full-year outlook has improved. Alyftrek is off to a good start and early launch metrics of Journa...

2 months ago - Seeking Alpha

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Susie Lisa - SVP, IR Reshma Kewalramani - CEO, President & Director Stua...

2 months ago - Seeking Alpha

Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta.

2 months ago - Reuters

Vertex Reports First Quarter 2025 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its tota...

2 months ago - Business Wire

Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

2 months ago - Benzinga

Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the first quarter, after the closing bell on Monday, May 5.

2 months ago - Benzinga

Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group

Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!

Other symbols: CMESPGI
2 months ago - CNBC Television

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...

2 months ago - Seeking Alpha

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

2 months ago - Seeking Alpha